After the immunohistochemistry screening, 12/105 cases emerged for the Trk protein expression, including 8/96 Ewing sarcomas, 3/5 USTS and 1/1 sarcoma with BCOR genetic alteration, with a comprehensive percentage of positive immunoreactivity of 11.4%. This evidence concerns the gene NTRK1 and sarcoma.